Bio Solution Co

Bio Solution Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Bio Solution Co (086820.KQ) as of Oct 22, 2026 is -8.10 %. In the previous year, Operating Cash Flow to Debt Ratio was 6.06 % — a change of -233.71% (lower).

OCF/Debt

-8.10 %

YoY

-233.71%

Last updated:

Operating Cash Flow to Debt Ratio of Bio Solution Co is 2024 -8.10 % . Operating Cash Flow to Debt Ratio of Bio Solution Co was 2023 6.06 % . It decreases by -233.71% lower compared to the previous year.

The Bio Solution Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
-342.46 KRW
Jan 1, 2020
-117.59 KRW
Jan 1, 2021
0.29 KRW
Jan 1, 2022
-11.51 KRW
Jan 1, 2023
6.06 KRW
Jan 1, 2024
-8.10 KRW
The Bio Solution Co OCF/Debt history
YEAROCF/DebtYoY
-8.10 %-233.71%
6.06 %-152.62%
-11.51 %-4,055.40%
0.29 %-100.25%
-117.59 %-65.66%
-342.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Solution Co Stock analysis

What does Bio Solution Co do? Bio Solution Co. Ltd. generates revenue through the manufacturing and distribution of cell therapy products and stem cell applied technologies. The company sells stem water, a cosmetic raw material containing human stem cells with whitening and anti-wrinkling effects, and keratinocyte medication for severe burns. Additionally, it offers chondrocyte therapy for arthritis treatment and develops human tissue models for toxicity and efficacy testing. The primary customers are cosmetic manufacturers and medical institutions seeking advanced therapeutic solutions. The firm's product portfolio includes stem water, keratinocyte medication, and chondrocyte therapy, all leveraging tissue engineering and stem cell technologies. These products target the cosmetic and medical sectors, with stem water appealing to the skincare market and keratinocyte and chondrocyte therapies serving medical applications. The company focuses on developing and commercializing cell-based solutions for both cosmetic and therapeutic uses. Bio Solution Co. Ltd. operates within the cell therapy and stem cell technology sector, providing specialized products that combine tissue engineering with stem cell applications. Its revenue streams are derived from the sale of cosmetic raw materials and medical therapeutics, with an emphasis on innovative, science-backed solutions for skin care and medical treatments. Bio Solution Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Solution Co stock

Operating Cash Flow to Debt Ratio of Bio Solution Co is -8.10 % in 2024.

Operating Cash Flow to Debt Ratio of Bio Solution Co changed from 6.06 % to -8.10 %, representing a -233.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Bio Solution Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Bio Solution Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Solution Co

All Key Metrics — Bio Solution Co